Introduction
============

Japanese and overseas guidelines define chronic obstructive pulmonary disease (COPD) as an inflammatory disease of the lung.[@b1-copd-11-295],[@b2-copd-11-295] Increasing evidence suggests that COPD is a multicomponent disease involving both systemic and pulmonary inflammation.[@b3-copd-11-295],[@b4-copd-11-295] Cigarette smoking is a major risk factor for COPD and long-term smoking can cause airway inflammation characterized by neutrophil, macrophage, and activated T lymphocyte infiltration as well as increased cytokine concentrations, including tumor necrosis factor (TNF)-α and interleukin (IL)-8.[@b5-copd-11-295] A previous in vitro study using human monocyte-derived macrophages showed that cigarette smoke enhanced IL-8 release in a time- and concentration-dependent manner.[@b6-copd-11-295]

Inflammatory biomarkers are becoming a useful means of characterizing the extent of both airway and systemic inflammation associated with COPD.[@b7-copd-11-295]--[@b9-copd-11-295] However, serum and sputum inflammatory biomarkers have not been studied extensively in Japanese patients with COPD. Ishikawa et al were the first to conduct a study in which inflammatory markers were measured in Japanese patients with COPD, and compared against levels in smokers and nonsmoking controls (NSC).[@b7-copd-11-295] Trends were seen with increased levels of inflammatory cells and biomarkers in sputum and blood in COPD.[@b7-copd-11-295] These findings were consistent with previous reports in Western studies[@b10-copd-11-295],[@b11-copd-11-295] in which sputum neutrophils, IL-8, surfactant protein-D and Krebs von den Lungen-6, serum clara cell 16, high sensitivity C-reactive protein, and plasma fibrinogen were higher in COPD patients compared to NSC.

Chronic bronchitis in cigarette smokers shares many clinical and histological features with environmental lung diseases attributed to the bacterial endotoxin, lipopolysac-charide (LPS). LPS is a biologically active component of tobacco smoke and is one of the most potent proinflammatory stimuli known.[@b12-copd-11-295] Bacterial infections are one of the dominant causes of acute exacerbations in COPD with LPS being the most abundant component within the cell wall of Gram-negative bacteria.[@b13-copd-11-295] LPS can stimulate the release of proinflammatory cytokines, including TNF-α, leading to an acute inflammatory response toward pathogens.[@b13-copd-11-295],[@b14-copd-11-295] LPS has been extensively used in models of inflammation because it mimics inflammatory effects of cytokines.[@b13-copd-11-295]

TNF-α is secreted by LPS-stimulated macrophages and is also produced by many different cell types including monocytes, fibroblasts, and endothelial cells.[@b15-copd-11-295] TNF-α is elevated in smokers[@b5-copd-11-295] and COPD patients.[@b16-copd-11-295],[@b17-copd-11-295] COPD and tobacco smoke may prime inflammatory cells thus increasing the inflammatory response in COPD patients and smokers compared to nonsmokers. It is possible to investigate this "priming" with the use of LPS and TNF-α stimulation since LPS induction is known to produce neutrophilic systemic and pulmonary inflammatory responses[@b18-copd-11-295],[@b19-copd-11-295] while experimental animal models show that TNF-α overexpression induces pathological changes similar to emphysema and pulmonary fibrosis.[@b15-copd-11-295]

In this study, we compared the release of pulmonary and systemic inflammatory mediators with and without stimulation by LPS or TNF-α to investigate if inflammatory cells in COPD show an increased responsiveness compared with non-COPD smokers and non-COPD nonsmokers. This is the first study of its type in Japanese subjects. It helps to further characterize COPD-related inflammation and support treatment of the disease in Japan.

Materials and methods
=====================

Subjects
--------

Japanese men and women, aged 40 years or older, were enrolled into one of three groups: 1) Patients with COPD (COPD group): subjects with a diagnosis of COPD[@b2-copd-11-295] who were current or ex-smokers with a ≥10 pack-year history of smoking, forced expiratory volume in 1 second/forced vital capacity (FEV~1~/FVC) \<0.7 at 15--60 minutes following use of a salbutamol inhaler and had cough or sputum symptoms during 2 weeks before collection of the study specimens; 2) non-COPD smokers (smoking controls \[SC\] group): current or ex-smokers with a ≥10 pack-year history of smoking and FEV~1~/FVC ≥0.7 at 15--60 minutes following use of a salbutamol inhaler; and 3) non-COPD, nonsmokers (NSC group): subjects who had not smoked within 6 months before the study visit, had a ≤1 pack-year history of smoking, and a FEV~1~/FVC ≥0.7 at 15--60 minutes following use of a salbutamol inhaler.

Subjects were excluded if they had a diagnosis of bronchial asthma or any respiratory disorder other than COPD, had undergone lung volume reduction or lung transplant, had a chest X-ray (or computed tomography scan) indicating a major disease other than COPD which may interfere with study assessments, had a respiratory infection within 4 weeks before screening, used inhaled corticosteroids and systemic corticosteroids or low-dose xanthines (use at a regular dose was allowable) within 4 weeks before screening, had a bacterial infection, viral infection (including viral hepatitis) or systemic inflammation at enrolment, or had a known α1-antitrypsin deficiency. Undesirable medical events, including serious adverse events, were monitored during the visits.

Study design
------------

This was a nontreatment, ex vivo study conducted between March 21, 2013 (first subject's first visit) and December 11, 2013 (last subject's last visit) at the Division of Respirology, Kurume University School of Medicine, Fukuoka Prefecture, Japan, in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Kurume University School of Medicine. Eligible subjects attended the hospital to provide written informed consent following the provision of study details and prior to any assessments. At this visit, cough and sputum symptoms were assessed, FEV~1~ and FVC were measured,[@b20-copd-11-295] blood and sputum samples were collected, and a chest X-ray was done if subjects had not had one within 6 months of the visit.

### Sputum induction

Sputum was induced by the method described by the European Task Force[@b21-copd-11-295] used in other studies.[@b7-copd-11-295],[@b22-copd-11-295] Briefly, after inhaling 200 μg of salbutamol (GlaxoSmithKline, Japan), subjects inhaled an aerosol of 3%, 4%, and 5% hypertonic saline for 7 minutes each from an ultrasonic nebulizer (NE-U07; Omron, Kyoto, Japan).

### Cell preparation

Induced sputum was processed as described by Pizzichini et al.[@b23-copd-11-295] Briefly, four-parts 0.1% dithiothreitol (Merck Millipore, Billerica, MA, USA) was added to one part sputum and incubated for 15 minutes, before four-parts phosphate-buffered saline was added.

Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood using a density gradient (Accu-Prep; Bioneer Corporation, Daejeon, Korea). Total cell counts of PBMC and sputum were performed using a hemocytometer and expressed as the number of cells per milliliter.

Sputum cells were pelleted by centrifugation and the supernatant was removed. PBMC and sputum cell pellets were then resuspended in Roswell Park Memorial Institute (RPMI) 1640 (Thermo Fisher Scientific, Waltham, MA, USA) with 10% fetal bovine serum (FBS) (Thermo Fisher Scientific) and 100× antibiotic-antimycotic solution (Thermo Fisher Scientific) at 0.75×10^6^/mL (live cells were identified using trypan-blue staining). However, sputum cells after cytospin were stained using May--Giemsa method, and a 1,000-differential cell count was performed on each slide by a single observer blind to the clinical data; the mean count from two slides per subject was used for analysis.

### Cell culture

PBMC and sputum cells (0.75×10^6^ cells/mL) were incubated in RPMI 1640 with 10% FBS medium (5% carbon dioxide, 37°C) with or without LPS (Sigma-Aldrich Co., St Louis, MO, USA) or human recombinant TNF-α (R&D Systems Inc., Minneapolis, MN, USA). A concentration--response curve for LPS or TNF-α stimulation of PBMC and sputum cell IL-8 release was carried out (data on file) and LPS 100 ng/mL was selected, in each case, as the optimal concentration for cytokine release. This agrees with previous reports.[@b24-copd-11-295] Similarly, a time course for LPS stimulation of PBMC IL-8 was carried out (data on file) and 18 hours was selected as the optimal time for incubation. This also agrees with previous reports.[@b25-copd-11-295] The resulting supernatants were isolated and stored at −80°C for the enzyme-linked immunosorbent assay.

### Measurement of biomarkers

Biomarkers were selected based on a previous study[@b7-copd-11-295] and have been used in Western population studies.[@b26-copd-11-295]

Human IL-6, IL-8, TNF-α, and matrix metalloproteinase (MMP)-9 levels were measured by commercial enzyme-linked immunosorbent assay kits. The minimum detection limits of human IL-6 (R&D Systems), IL-8 (R&D Systems), TNF-α (R&D Systems), and MMP-9 (GE Healthcare, Amersham, Buckinghamshire, UK) were 2.0, 31.3, 15.6, and 1,000 pg/mL, respectively. A half value limit of detection for each biomarker was used for statistical analysis when levels were not detected.

Statistical methods
-------------------

Thirty subjects were enrolled, as planned, with ten subjects per group. This sample size allowed for possible incompleteness of data in some subjects since obtaining sputum from NSC can be difficult; it was based on a similar study previously conducted in the UK which compared LPS-induced IL-8 expression in PBMC between COPD and SC with eight subjects per group (GlaxoSmithKline data on file).

Our primary objective was to measure the inflammatory biomarker release pre- and poststimulation by LPS or TNF-α in PBMC and sputum cells. Differences were calculated between basal and stimulated release of each biomarker to overcome variability between samples. Release of inflammatory biomarkers was analyzed as follows: Dunnett's multicomparison, nonparametric, test to compare the COPD group versus the SC and NSC groups. The level of significance was 5%. Stratified analyses were conducted according to subject baseline factors. The per protocol set was the primary data set for analysis. Correlation between variables was assessed using Spearman's rank correlation coefficient.

Results
=======

Subject population
------------------

All enrolled subjects complied with the protocol and were included in the analyses as the per protocol set. [Table 1](#t1-copd-11-295){ref-type="table"} summarizes the demographics and baseline characteristics. The mean FEV~1~/FVC (%) ± standard deviation was 39.6±17.9 in COPD, 77.0±5.6 in SC, and 79.5±4.2 in NSC, confirming that patients with COPD had been recruited. No adverse events were reported throughout the study period.

Stimulation of cellular release in PBMC and sputum
--------------------------------------------------

There was an increase in basal TNF-α release in both the COPD and SC groups (COPD: 81.6±111.4; SC: 80.3±95.7; and NSC: 9.5±5.2 pg/mL) and this was statistically significant (*P*\<0.05) between COPD and NSC ([Table S1](#SD1-copd-11-295){ref-type="supplementary-material"}; [Figure 1](#f1-copd-11-295){ref-type="fig"}). In PBMC, there was a tendency in all three subject groups for increased biomarker release following TNF-α or LPS stimulation ([Table 2](#t2-copd-11-295){ref-type="table"}). The greatest changes were generally seen in COPD, with the cellular release of IL-8 and MMP-9 being higher after TNF-α stimulation and MMP-9 and TNF-α higher after LPS stimulation ([Figure 2A](#f2-copd-11-295){ref-type="fig"}; [Table 2](#t2-copd-11-295){ref-type="table"}). No significant differences were seen in other biomarkers before or after stimulation.

In sputum cells, there were inconsistent findings pre- and poststimulation with either TNF-α or LPS. Indeed, following LPS stimulation, the greatest mean release of IL-8 and TNF-α tended to be in the NSC group compared with COPD and SC groups ([Figure 2B](#f2-copd-11-295){ref-type="fig"}; [Table 2](#t2-copd-11-295){ref-type="table"}). No significant differences were seen between subject groups across all biomarkers with or without stimulation.

Sputum inflammatory cell counts and correlations
------------------------------------------------

There were no significant differences in total cell counts and the numbers and percentages of neutrophils, macrophages, lymphocytes, and eosinophils in induced sputum among the COPD, SC, and NSC groups ([Table 3](#t3-copd-11-295){ref-type="table"}). However, the mean total cell count and mean number of neutrophils and eosinophils tended to be the highest in COPD followed by SC and then NSC ([Table 3](#t3-copd-11-295){ref-type="table"}). In contrast, the highest number of macrophages was seen in NSC followed by SC and then COPD.

Statistically significant correlations were seen between inflammatory cells and biomarkers across all three subject groups ([Table 3](#t3-copd-11-295){ref-type="table"}). Significant correlations were seen between the number of macrophages and %macrophages and IL-8, IL-6, and TNF-α ([Table 4](#t4-copd-11-295){ref-type="table"}). Significant correlations were also seen between %neutrophils and IL-8, IL-6, and TNF-α. No correlations were seen with MMP-9 ([Table 4](#t4-copd-11-295){ref-type="table"}).

Discussion
==========

The objective of our study was to compare inflammatory cell responsiveness to stimulation between Japanese patients with COPD, SC, and NSC. We measured the release of inflammatory biomarkers from PBMC and sputum cells before and after stimulation to investigate whether there were differences between these three subject groups.

Firstly, there was a significant difference in basal TNF-α release from PBMC between the COPD and NSC groups. Secondly, there was increased biomarker release following stimulation with TNF-α or LPS, with the highest increases tending to be in the COPD group: For example, after stimulation, there was a small increase in MMP-9 release in cells from the SC and NSC groups, but an approximately tenfold increase in the COPD group. This was also apparent in LPS-induced TNF-α release, for which there was a greater than sixfold increase in PBMC from the COPD group, compared with NSC ([Table 2](#t2-copd-11-295){ref-type="table"}). Together, these observations suggest that PBMC may be primed in the circulation in COPD, which agrees with previous findings in Western populations[@b27-copd-11-295],[@b28-copd-11-295] and supports the concept of systemic inflammation being important in COPD.

Sputum cell data were more variable and less conclusive than those from PBMC. This may be because sputum samples are more heterogeneous and contain a variety of cells, which may have increased the variability in biomarker release. Of particular interest is that following LPS stimulation, the greatest increase in TNF-α and IL-8 release was seen in the NSC group rather than in either of the COPD and SC groups ([Table 2](#t2-copd-11-295){ref-type="table"}).

The apparent contrast between the response to LPS stimulation of circulating PBMC and resident sputum cells in both the SC and COPD groups may be explained by the fact that sputum cells, unlike PBMC, may have been de-sensitized possibly by prior exposure to LPS in cigarette smoke in the airways. Alternatively, as our results show, the predominant cells in sputum, in both SC and COPD, are neutrophils, which have been reported to show only a modest response to LPS stimulation.[@b29-copd-11-295]

Following stimulation, the release of inflammatory mediators from PBMC was increased in both SC and COPD, compared with NSC. This suggests that circulating cells may be activated by smoking, with or without COPD, and that smoking, per se, may directly or indirectly increase systemic inflammation.

COPD is associated with systemic and pulmonary inflammation,[@b3-copd-11-295],[@b4-copd-11-295] but it remains unclear how the systemic inflammation arises: Is it due to the spillover of inflammation from the lungs? Or, does systemic inflammation occur in parallel to the pulmonary inflammation and over time may even enhance it?[@b3-copd-11-295],[@b16-copd-11-295] Our results show that inflammation is present in both the blood and airways of smokers and patients with COPD, but we cannot determine the order in which systemic and pulmonary inflammatory components arise.

The levels of sputum inflammatory total cells, neutrophils, and macrophages tended to vary across the subject groups ([Table 3](#t3-copd-11-295){ref-type="table"}). Neutrophil levels were higher in the COPD group than either control group indicating that neutrophils are part of the inflammatory response in COPD. This concurs with previous data in Japanese subjects.[@b7-copd-11-295] In contrast, macrophage levels were lower in patients with COPD than either control group suggesting that macrophages may be consumed by the inflammatory process and this confirms previous observations.[@b7-copd-11-295],[@b30-copd-11-295],[@b31-copd-11-295]

Significant correlations were seen among inflammatory cells, %macrophages, and %neutrophils with biomarkers IL-8, IL-6, and TNF-α across all three subject groups, which agrees with previous data in a Japanese COPD population in which significant correlations were observed between IL-8 and neutrophils and IL-8 and macrophages.[@b7-copd-11-295] Neutrophils are a source of IL-8[@b10-copd-11-295],[@b32-copd-11-295] and our data provide further evidence that IL-8 may be secreted into sputum to act as a chemoattractant for neutrophils migrating into the airway. Furthermore, IL-8 is synthesized by various cell types including neutrophils and macrophages[@b10-copd-11-295] and so the correlation seen in our study is not surprising. TNF-α has a broad spectrum of inflammatory effects in COPD resulting in the activation of various cells, including neutrophils and macrophage precursors, monocytes.[@b10-copd-11-295] IL-6 exerts proinflammatory effects in COPD, initiating the acute phase response, while IL-6 trans-signaling controls macrophage recruitment during acute inflammation.[@b33-copd-11-295]

Study limitations and strengths
-------------------------------

Our study design had a number of limitations. The number of subjects studied was low and this may have prevented us from clearly defining differences between the groups. Biomarker data are known to be variable and our sample size was insufficient to overcome this variability. In addition, direct measurement of inflammatory biomarkers in peripheral blood is known to be difficult due to their short half-lives, low concentrations, and their binding to soluble receptors and the effects of renal clearance.[@b34-copd-11-295],[@b35-copd-11-295] In addition, the bio-marker assay kits were originally developed for plasma and serum. Larger sample sizes would be needed to investigate these effects further. We did not assess sputum cell (largely comprising neutrophils) viability after incubation, which is known to be affected by TNF-α and LPS and this omission may have been additionally responsible for the variability in the sputum data. Furthermore, a comparison of sputum and blood cellular data was difficult because of the differences in cell populations between the two sample types. Isolating specific inflammatory cell types from each medium would enable comparisons to be made and correlations explored. As a single-center study, consistency in the sampling and analysis methodology was a possible strength.

Conclusion
==========

This was the first study in which inflammatory cell mediator release before and after stimulation was compared among Japanese COPD, SC, and NSC groups. Our results suggest preactivation of circulating inflammatory cells such as PBMC in patients with COPD. In addition, this finding provides further evidence that COPD is a multicomponent disease, involving both airway and systemic inflammation.

Supplementary material
======================

###### 

Summary of biomarkers in peripheral blood mononuclear cells (stimulated by TNF-α or LPS)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Inflammatory cells   Non-COPD NSC group\                                     Non-COPD SC group\   COPD group\                                                                                                                        
                       (N=10)                                                  (N=10)               (N=10)                                                                                                                             
  -------------------- ------------------------------------------------------- -------------------- ------------------------------------------------------- ------------------ ------------------------------------------------------- -------------------
                       (−)TNF-α                                                (+)TNF-α             (−)TNF-α                                                (+)TNF-α           (−)TNF-α                                                (+)TNF-α

  IL-8, pg/mL          421.8±361.5                                             3,942.1±3,293.4      525.5±360.0                                             3,155.5±1,796.6    315.8±155.0                                             4,462.8±3,087.4

  IL-6, pg/mL          3.0±4.7                                                 44.4±63.1            50.6±89.2                                               13.9±12.0          3.6±6.6                                                 44.25±91.9

  MMP-9, pg/mL         500.0±0.0[b](#tfn17-copd-11-295){ref-type="table-fn"}   768.3±442.2          500.0±0.0[b](#tfn17-copd-11-295){ref-type="table-fn"}   943.9±679.4        500.0±0.0[b](#tfn17-copd-11-295){ref-type="table-fn"}   3,133.2±4,630.7

                       (−)LPS                                                  (+)LPS               (−)LPS                                                  (+)LPS             (−)LPS                                                  (+)LPS

  IL-8, pg/mL          421.8±361.5                                             47,303.5±24,858      525.5±360.0                                             35,473.7±9,802.1   315.8±155.0                                             34,508.5±15,412.7

  IL-6, pg/mL          3.0±4.7                                                 7,312.7±5,512.9      50.6±89.2                                               8,030.0±3,340.4    3.6±6.6                                                 8,397.1±3,203.8

  MMP-9, pg/mL         500.0±0.0[b](#tfn17-copd-11-295){ref-type="table-fn"}   792.3±508.3          500.0±0.0[b](#tfn17-copd-11-295){ref-type="table-fn"}   946.0±697.3        500.0±0.0[b](#tfn17-copd-11-295){ref-type="table-fn"}   3,497.4±5,267.0

  TNF-α, pg/mL         9.5±5.2[a](#tfn16-copd-11-295){ref-type="table-fn"}     1,305.4±840.7        80.3±95.7                                               4,500.2±4,453.8    81.6±111.4                                              8,228.5±20,171.3
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** All data are expressed as mean ± standard deviation.

*P*\<0.05 (difference between COPD groups and non-smokers, by the Dunnett's test); (+) with stimulation, (−) without stimulation.

The levels of MMP-9 before stimulation with TNF-α were below the limit of detection (1,000 pg/mL).

**Abbreviations:** COPD, chronic obstructive pulmonary disease; IL-8, interleukin-8; IL-6, interleukin-6; LPS, lipopolysaccharide; MMP-9, matrix metalloproteinase-9; SC, smoking controls; NSC, nonsmoking controls; TNF-α, tumor necrosis factor-alpha.
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![Basal release of TNF- α (pg/mL) from PBMCs in patients with COPD, non-COPD SC, and non-COPD NSC.\
**Notes:** Data are presented as mean ± standard deviation; n=10 in each group. ^a^Difference between COPD and non-COPD NSC groups by Dunnett's test.\
**Abbreviations:** TNF-α, tumor necrosis factor-alpha; LPS, lipopolysaccharide; COPD, chronic obstructive pulmonary disease; SC, smoking controls; NSC, nonsmoking controls; PBMCs, peripheral blood mononuclear cells.](copd-11-295Fig1){#f1-copd-11-295}

![LPS-induced TNF-α release (pg/mL) from PBMC (**A**) and sputum cells (**B**) in patients with COPD, non-COPD SC, and non-COPD NSC.\
**Notes:** Data are presented as mean ± standard deviation; N=10 in each group.\
**Abbreviations:** TNF-α, tumor necrosis factor-alpha; LPS, lipopolysaccharide; COPD, chronic obstructive pulmonary disease; SC, smoking controls; NSC, nonsmoking controls; PBMC, peripheral blood mononuclear cells.](copd-11-295Fig2){#f2-copd-11-295}

###### 

Summary of subject demographics and baseline characteristics

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
  Demographics and measurements   Non-COPD NSC group\                                   Non-COPD SC group\                                    COPD group\
                                  (N=10)                                                (N=10)                                                (N=10)
  ------------------------------- ----------------------------------------------------- ----------------------------------------------------- -------------
  Demographics                                                                                                                                

   Age, years                     69.4±5.2                                              64.8±7.8                                              62.2±6.6

   Sex, males/females             5/5                                                   9/1                                                   7/3

   Height, cm                     158.3±4.3                                             165.7±7.0                                             159.9±6.8

   Weight, kg                     59.3±11.2                                             63.0±10.5                                             48.9±7.3

  Smoking history                                                                                                                             

   Current/former/never           0/0/10                                                8/2/0                                                 3/7/0

   Number of pack-years           0                                                     44.3±35.0                                             65.4±30.2

  Spirometry                                                                                                                                  

   FVC, L                         3.1±0.9[a](#tfn1-copd-11-295){ref-type="table-fn"}    3.8±0.9[b](#tfn2-copd-11-295){ref-type="table-fn"}    2.8±0.8

   FEV~1~, L                      2.4±0.7[c](#tfn3-copd-11-295){ref-type="table-fn"}    2.9±0.7[d](#tfn4-copd-11-295){ref-type="table-fn"}    1.2±0.9

  FEV~1~, %predicted              79.5±4.2[d](#tfn4-copd-11-295){ref-type="table-fn"}   76.6±5.8[c](#tfn3-copd-11-295){ref-type="table-fn"}   40.4±17.6

  FEV~1~/FVC, %                   79.5±4.2[d](#tfn4-copd-11-295){ref-type="table-fn"}   77.0±5.6[c](#tfn3-copd-11-295){ref-type="table-fn"}   39.6±17.9
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

*P*\<0.05,

*P*\<0.01,

*P*\<0.005, and

*P*\<0.0001 (difference between COPD group and non-COPD NSC group/non-COPD SC group, by Dunnett's test).

**Abbreviations:** COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; SC, smoking controls; NSC, nonsmoking controls.

###### 

Summary of the differences in biomarker levels before and after stimulation in PMBC and induced sputum cells (all subjects)

  Inflammatory biomarkers                                              Non-COPD NSC group (N=10)   Non-COPD SC group (N=10)   COPD group (N=10)
  -------------------------------------------------------------------- --------------------------- -------------------------- --------------------
  PBMC: Mean ± SD difference (pre- and poststimulation with TNF-α)                                                            
   IL-8, pg/mL                                                         3,520.3±2,979.1             2,630.0±1,977.2            4,147.0±2,974.5
   IL-6, pg/mL                                                         41.4±59.7                   −36.7±92.2                 40.7±85.7
   MMP-9, pg/mL                                                        268.3±442.2                 443.9±679.4                2,633.2±4,630.7
  PBMC: Mean ± SD difference (pre- and poststimulation with LPS)                                                              
   IL-8, pg/mL                                                         46,881.7±24,615.3           34,948.2±9,743.3           34,192.7±15,365.8
   IL-6, pg/mL                                                         7,309.7±5,511.0             7,979.4±3,285.2            8,393.5±3,200.5
   MMP-9, pg/mL                                                        292.3±508.3                 446.0±697.3                2,997.4±5,267.0
   TNF-α, pg/mL                                                        1,296.0±841.6               4,419.9±4,421.3            8,146.9±20,195.6
  Sputum: Mean ± SD difference (pre- and poststimulation with TNF-α)                                                          
   IL-8, pg/mL                                                         −9,191.8±22,715.9           −619.1±17,886.7            2,714.0 ± 11,359.2
   IL-6, pg/mL                                                         −446.4±1,223.5              556.3±2,855.3              62.1±716.4
   MMP-9, pg/mL                                                        −801.4±2,643.3              −726.9±1,971.3             −311.3±974.9
  Sputum: Mean ± SD difference (pre- and poststimulation with LPS)                                                            
   IL-8, pg/mL                                                         20,785.4±48,223.6           1,175.8±2,180.1            2,885.3±15,438.1
   IL-6, pg/mL                                                         1,702.2±2,549.0             −45.3±173.5                1,496.9±2,615.2
   MMP-9, pg/mL                                                        −1,011.5±2,926.7            −39.0±321.4                132.6±2,715.0
   TNF-α, pg/mL                                                        9,773.4±26,966.8            2,533.8±14,710.9           3,589.3±8,590.8

**Abbreviations:** COPD, chronic obstructive pulmonary disease; IL-8, interleukin-8; IL-6, interleukin-6; LPS, lipopolysaccharide; MMP-9, matrix metalloproteinase-9; SC, smoking controls; NSC, nonsmoking controls; PBMC, peripheral blood mononuclear cells; SD, standard deviation; TNF-α, tumor necrosis factor-alpha.

###### 

Inflammatory cell counts in sputum

  Inflammatory cells                  Sputum cell count                       
  ----------------------------------- ------------------- ------------------- -------------------
  Total cell count, ×10^5^ cells/mL   8,433.0±4,822.1     19,027.6±20,716.7   26,059.1±48,773.9
  Neutrophils, ×10^5^ cells/mL        7,235.9±4,727.2     17,573.1±20,508.7   24,528.6±48,376.7
  Macrophages, ×10^5^ cells/mL        1,029.4±780.7       1,191.8±725.7       831.7±775.1
  Lymphocytes, ×10^5^ cells/mL        0.7±0.8             0.5±0.5             0.6±1.0
  Eosinophils, ×10^5^ cells/mL        0.9±1.3             2.2±5.2             6.4±12.2

**Note:** All data are expressed as mean ± standard deviation.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; SC, smoking controls; NSC, nonsmoking controls.

###### 

Correlations between sputum inflammatory cell counts and sputum biomarkers in all subjects

  Inflammatory cells           Sputum                                                                                                          
  ---------------------------- --------------------------------------------------- --------------------------------------------------- ------- --------------------------------------------------
  Absolute number                                                                                                                              
   Total cells                 −0.28                                               −0.27                                               0.20    −0.10
   Neutrophils                 −0.34                                               −0.31                                               0.22    −0.13
   Macrophages                 0.56[c](#tfn11-copd-11-295){ref-type="table-fn"}    0.48[b](#tfn10-copd-11-295){ref-type="table-fn"}    0.19    0.49[b](#tfn10-copd-11-295){ref-type="table-fn"}
  Cell differentiation                                                                                                                         
   Percentage of neutrophils   −0.69[e](#tfn13-copd-11-295){ref-type="table-fn"}   −0.63[d](#tfn12-copd-11-295){ref-type="table-fn"}   0.18    −0.41[a](#tfn9-copd-11-295){ref-type="table-fn"}
   Percentage of macrophages   0.72[e](#tfn13-copd-11-295){ref-type="table-fn"}    0.64[d](#tfn12-copd-11-295){ref-type="table-fn"}    −0.12   0.49[b](#tfn10-copd-11-295){ref-type="table-fn"}

**Notes:**

*P*\<0.05,

*P*\<0.01,

*P*\<0.005,

*P*\<0.0005, and

*P*\<0.0001 (correlation between variables, by Spearman's rank correlation coefficient).

**Abbreviations:** IL-8, interleukin-8; IL-6, interleukin-6; MMP-9, matrix metalloproteinase-9; TNF-α, tumor necrosis factor-alpha.
